This repository is under review for potential modification in compliance with Administration directives.

← Back to Approved DARs

Alzheimer's Disease Genomics: Systems Biology and Endophenotypes

PI
Saykin, Andrew
DAR ID
10023
Initial Approval Date
November 15, 2018
Current DAR Status
Active
PI Institution
Indiana University School of Medicine
PI Institution Country
United States
PI Institution Type
Non-Profit

Requested Datasets (2)

NG00067Alzheimer's Disease Sequencing Project Umbrella StudyNG00100Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis. Kunkle et al. (2021)

Research Use Statement
Alzheimer’s disease (AD) and related genomic data sets including sequencing, GWAS and phenotypic data will be combined with longitudinal clinical, demographic, cognitive, MRI, PET, CSF and blood endophenotype data, where available, to investigate the genetic architecture of Alzheimer’s disease and related disorders (ADRD) and brain aging. The overall goal to gain a better understanding of fundamental disease mechanisms, genetic susceptibility and protective factors, and the relationship of genetic factors to disease heterogeneity, progression and different trajectories across biomarker profiles. Data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) will be combined with ADSP and other data sets to increase detection power and for replication across samples. Analyses will include conventional statistical association, multivariate profiling of endophenotypes, biological pathway and network approaches, longitudinal models and combinatorial machine learning. Deliverables will include reports of new prioritized lists of candidate genes and variants for further investigation in new samples, functional experiments and in model systems. The ultimate goal is discovery of novel potential diagnostic markers and therapeutic targets that will help provide the foundation for a precision medicine approach to AD/ADRD.

Non-Technical Summary
Alzheimer’s disease (AD) and related genomic data sets will be combined with longitudinal clinical, demographic, cognitive, MRI, PET, CSF and blood biomarker data to investigate the genetic architecture of Alzheimer’s disease and related disorders (ADRD) and brain aging. The overall goal to gain a better understanding of fundamental disease mechanisms, genetic susceptibility and protective factors, and the relationship of genetic factors to disease heterogeneity, progression and different trajectories across biomarker profiles. Data will be combined across studies to increase detection power and for replication. Analyses will include conventional statistical association and advanced analytic approaches including multivariate profiling, biological pathway and network analysis and machine learning. The ultimate goal is discovery of novel potential diagnostic and therapeutic markers that will help provide the foundation for a precision medicine approach to AD/ADRD.

Reported Publications (142)

Publications shown are those reported by investigators through NIAGADS DAR reporting and renewal processes and may not represent a complete list of publications associated with the project.

  1. Alzheimer's disease polygenic risk in early- and late-onset Alzheimer's disease. Pentchev JV, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. PMID: 41532810
  2. Amyloid-related default mode network hyperconnectivity and longitudinal decline in network distinctiveness in preclinical Alzheimer's disease. Cha WJ, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. PMID: 41612924
  3. APOE-stratified Proteomic and Metabolomic Analysis Reveals Mitochondrial Dysfunction Inflammation and Lipid Dysregulation in Alzheimer's Disease. Li F, et al. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2026. PMID: 41642643
  4. Associations of circulating c-reactive protein levels with central Alzheimer's disease biomarkers. Choi HJ, et al. The journal of prevention of Alzheimer's disease. 2026. PMID: 40967969
  5. Blood-Brain Network-Based Polygenic Risk Scores Reveal Biomarker Signatures and the Progression of Alzheimer's Disease. Goldstein D, et al. Journal of clinical medicine. 2026. PMID: 42074686
  6. Characterizing amyloid and tau positron emission tomography-based stages across the clinical continuum. Cody KA, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. PMID: 41505234
  7. Circulating lipids are related to longitudinal changes of ATN biomarkers for Alzheimer's disease. Kim JP, et al. Molecular psychiatry. 2026. PMID: 42304066
  8. Clinical impact of the Alzheimer's Disease Neuroimaging Initiative: A review of studies using ADNI data (2023 to June 2025). Kanoria S, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. PMID: 41988903
  9. Cognitive data harmonization in the ADRC Network and beyond-Past, present, and future. Crane PK, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. PMID: 41549411
  10. Combining post-mortem and neuroimaging measures of brain amyloidosis to accelerate genomic discovery. Wang TC, et al. Brain : a journal of neurology. 2026. PMID: 42334898
Show more
  1. Contributions of the Alzheimer's Disease Neuroimaging Initiative to advancing AD research: a targeted review of recent publications. Veitch DP, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. PMID: 42309987
  2. Epigenetic aging in Alzheimer's disease: Relation to proteome. Kim BH, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. PMID: 42554263
  3. Evaluating the association of apolipoprotein E genotype and cognitive resilience in SuperAgers. Durant A, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. PMID: 41542929
  4. Gene-Modulated Network Diffusion for Improved Modeling of Amyloid- β Spread in Alzheimer's Disease. Xu FH, et al. bioRxiv : the preprint server for biology. 2026. PMID: 42146687
  5. Genetic architecture of the limbic white matter microstructure in aging and Alzheimer's Disease. Lorenz AS, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. PMID: 42410730
  6. Genetic modifiers of APOE-ε4-associated cognitive decline. Contreras AG, et al. Nature communications. 2026. PMID: 41720779
  7. Heterogeneous patterns of cognitive decline in Alzheimer's disease across three domains of cognition. Scollard P, et al. Journal of Alzheimer's disease : JAD. 2026. PMID: 41603331
  8. Integrating polygenic and transcriptional risk scores for detecting Alzheimer's disease. Hwang J, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. PMID: 42080296
  9. Integrating real-world data with gold-standard longitudinal clinical and genomic data to advance precision medicine for the Alzheimer's Disease Research Center Program and beyond: a proof-of-concept data platform. Biber S, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. PMID: 41808605
  10. MicroRNA-181 influences Alzheimer's risk by regulating neprilysin and microtubule-associated tau pathways, offering a novel target. Wang R, et al. bioRxiv : the preprint server for biology. 2026. PMID: 42368021
  11. MIND diet moderates the associations between cerebrovascular and neurodegenerative disease burden and cognition. Dempsey DA, et al. Frontiers in nutrition. 2026. PMID: 42211091
  12. No significant associations between history of head injury and Alzheimer's disease fluid biomarkers in older adults. Dybing KM, et al. Journal of Alzheimer's disease : JAD. 2026. PMID: 41342653
  13. Predicting accumulation and age at onset of amyloid-β from genetic risk and resilience for Alzheimer's disease. O'Brien EK, et al. EBioMedicine. 2026. PMID: 42284682
  14. Predicting Autopsy-Confirmed Neuropathology across Clinical, Neuroimaging, and CSF Biomarkers using Machine Learning. Patterson C, et al. bioRxiv : the preprint server for biology. 2026. PMID: 42239211
  15. Sex-specific genetic drivers of memory, executive functioning and language in older adults. Eissman JM, et al. Brain : a journal of neurology. 2026. PMID: 41989867
  16. Systems biology of Alzheimer's Disease: a scoping review of key pathways and mechanisms. Bice PJ, et al. Molecular neurodegeneration. 2026. PMID: 41731612
  17. The Metabolome as a Readout for Adverse Social Exposome Influences on Human Health - A Roadmap for Modifiable Factors and Proactive Health. Liang N, et al. medRxiv : the preprint server for health sciences. 2026. PMID: 41674595
  18. A DAT1 gene and APOE ε4 interaction is associated with apathy and structural brain changes in mild cognitive impairment and Alzheimer's disease. Malik R, et al. Journal of Alzheimer's disease : JAD. 2025. PMID: 39610284
  19. A multi-ancestry polygenic risk score for Alzheimer disease is associated with cognitive decline, hippocampal atrophy and neuropathological hallmarks in diverse populations. Kurniansyah N, et al. medRxiv : the preprint server for health sciences. 2025. PMID: 41040715
  20. A seven-year longitudinal study of the Alzheimer's disease blood metabolome. Marella B, et al. medRxiv : the preprint server for health sciences. 2025. PMID: 41409665
  21. ACE inhibition increases Alzheimer's disease risk by promoting tau phosphorylation. Kim MS, et al. medRxiv : the preprint server for health sciences. 2025. PMID: 40832424
  22. Addressing overfitting bias due to sample overlap in polygenic risk scoring. Jeong S, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 40189831
  23. Amyloid PET predicts longitudinal functional and cognitive trajectories in a heterogeneous cohort. Younes K, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 40145384
  24. Association between BrainAGE and Alzheimer's disease biomarkers. Abughofah Y, et al. Alzheimer's & dementia (Amsterdam, Netherlands). 2025. PMID: 40018325
  25. Association of Alzheimer's Disease Polygenic Risk Score with Concussion Severity and Recovery Metrics. Dybing KM, et al. Sports medicine (Auckland, N.Z.). 2025. PMID: 39821585
  26. Astrocyte Reactivity Polygenic Risk Score May Predict Cognitive Decline in Alzheimer's Disease. Phillips JM, et al. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing. 2025. PMID: 39670391
  27. Beyond NACC's Uniform Data Set for cognition: the impact of additional items on measurement precision. Choi SE, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 40960068
  28. Bridging the gap: addressing NACC's evolving cognition batteries across UDS versions. Lee ML, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 41266285
  29. Cell-specific transcriptional signatures of vascular cells in Alzheimer's disease: perspectives, pathways, and therapeutic directions. Chaudhuri S, et al. Molecular neurodegeneration. 2025. PMID: 39876020
  30. Cerebrospinal fluid proteins in relation to longitudinal cognitive trajectories. Kim BH, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 41216795
  31. Characterizing amyloid and tau PET-based stages across the clinical continuum. Cody KA, et al. medRxiv : the preprint server for health sciences. 2025. PMID: 41256116
  32. Comparable performance of the NACC Uniform Data Set version 3 neuropsychological test battery in assessing longitudinal cognitive change for African American and White participants. Chan KCG, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 41206462
  33. Comprehensive characterization of the RNA editing landscape in the human aging brains with Alzheimer's disease. Gupta AK, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 40631452
  34. Comprehensive characterization of the transcriptional landscape in Alzheimer's disease (AD) brains. Chen C, et al. Science advances. 2025. PMID: 39752483
  35. Deep fusion of incomplete multi-omic data for molecular mechanism of Alzheimer's disease. Xie L, et al. Scientific reports. 2025. PMID: 40825989
  36. Dynamic proportional loss of functional connectivity revealed change of left superior frontal gyrus in subjective cognitive decline: an explanatory study based on Chinese and Western cohorts. Wang L, et al. GeroScience. 2025. PMID: 39888585
  37. Evaluating the association of APOE genotype and cognitive resilience in SuperAgers. Durant A, et al. medRxiv : the preprint server for health sciences. 2025. PMID: 39830268
  38. Facets of language performance in early-onset and late-onset Alzheimer's disease dementia. Gallée J, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 40990522
  39. Facets of language performance in early-onset and late-onset Alzheimer's disease dementia. Gallée J, et al. medRxiv : the preprint server for health sciences. 2025. PMID: 40585112
  40. Feasibility of lifestyle interventions for cognition in adults with low education. Clark DO, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 40442881
  41. Functional insight into East Asian-specific genetic risk loci for Alzheimer's disease. Cho M, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 39991798
  42. Genetic architecture of the limbic white matter microstructure in aging and Alzheimer's Disease. Lorenz A, et al. medRxiv : the preprint server for health sciences. 2025. PMID: 40475163
  43. Genome-wide pleiotropy analysis of longitudinal blood pressure and harmonized cognitive performance measures. Kang M, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 40951946
  44. GWAS meta-analysis of CSF Alzheimer's disease biomarkers 18,948 individuals reveal novel loci and genes regulating lipid metabolism, brain volume and autophagy. Cruchaga C, et al. Research square. 2025. PMID: 40470240
  45. Individual bioenergetic capacity as a potential source of resilience to Alzheimer's disease. Arnold M, et al. Nature communications. 2025. PMID: 39994231
  46. Interaction of genetic variants and methylation in transcript-level expression regulation in Alzheimer's disease by multi-omics data analysis. Han S, et al. BMC genomics. 2025. PMID: 39979805
  47. Interplay between age, APOE Ɛ4 and the metabolome in plasma and brain in Alzheimer's disease. Amin N, et al. Translational psychiatry. 2025. PMID: 41173821
  48. LD-informed deep learning for Alzheimer's gene loci detection using WGS data. Jo T, et al. Alzheimer's & dementia (New York, N. Y.). 2025. PMID: 39822590
  49. Locus coeruleus tau is linked to successive cortical tau accumulation. Yi D, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 39641328
  50. Longitudinal non-linear changes in the microstructure of the hippocampal subfields in older adults. Zia G, et al. Neurobiology of aging. 2025. PMID: 40752038
  51. Longitudinal plasma proteomics: relation to incident Alzheimer's disease dementia and biomarkers. Lee EH, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 41246827
  52. MG-TCCA: Tensor Canonical Correlation Analysis Across Multiple Groups. Zhou Z, et al. IEEE transactions on computational biology and bioinformatics. 2025. PMID: 39348263
  53. miR-423-5p and miR-92a-3p in Alzheimer's disease: relationship with pathology and cognition. Han SW, et al. Frontiers in aging neuroscience. 2025. PMID: 40766177
  54. Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies known and novel cross-population and ancestry-specific associations as novel risk loci for Alzheimer's disease. Rajabli F, et al. Genome biology. 2025. PMID: 40676597
  55. Multi-Modal Deep Clustering Survival Machines for Alzheimer's Disease Subtype Discovery. Wen Z, et al. ... IEEE International Conference on Computer Vision workshops. IEEE International Conference on Computer Vision. 2025. PMID: 41743930
  56. Multi-modal Imaging-based Pseudotime Analysis of Alzheimer progression. He B, et al. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing. 2025. PMID: 39670403
  57. Multi-omics analysis for identifying cell-type-specific and bulk-level druggable targets in Alzheimer's disease. Liu S, et al. Journal of translational medicine. 2025. PMID: 40653482
  58. Multi-Omics Analysis for Identifying Cell-Type-Specific Druggable Targets in Alzheimer's Disease. Liu S, et al. medRxiv : the preprint server for health sciences. 2025. PMID: 39830273
  59. Multi-site video-based assessment with the NACC UDS-Version 3 battery: Design and participant experience in the V-Cog study. Sachs BC, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 41137629
  60. Novel modelling approaches to elucidate the genetic architecture of resilience to Alzheimer's disease. Phillips JM, et al. Brain : a journal of neurology. 2025. PMID: 40111762
  61. Novel set of plasma proteins classifies Alzheimer's dementia in African American individuals with high accuracy. Kuchenbecker LA, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 40717652
  62. Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials. Weiner MW, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 39711072
  63. Plasma proteomic Alzheimer's risk score: Biological age clock and pseudotime trajectory. Liu S, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 41157910
  64. Plasma proteomic analysis identifies proteins and pathways related to Alzheimer's risk. Huang YN, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 40810263
  65. Polygenic risk score predicts pathologically confirmed cerebral amyloid angiopathy. Pyun JM, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 41383049
  66. Predicting accumulation and age at onset of amyloid-β from genetic risk and resilience for Alzheimer's disease. O'Brien EK, et al. Research square. 2025. PMID: 41282187
  67. Protein-based Diagnosis and Analysis of Co-pathologies Across Neurodegenerative Diseases: Large-Scale AI-Boosted CSF and Plasma Classification. Xu Y, et al. Research square. 2025. PMID: 40766224
  68. Protein-based Diagnosis and Analysis of Co-pathologies Across Neurodegenerative Diseases: Large-Scale AI-Boosted CSF and Plasma Classification. Xu Y, et al. medRxiv : the preprint server for health sciences. 2025. PMID: 40672487
  69. Real-world observations on neuroinflammation-related drug responses in Alzheimer's disease. Xu J, et al. Journal of Alzheimer's disease : JAD. 2025. PMID: 40938773
  70. Retinal vascular biomarkers in mild cognitive impairment and Alzheimer's disease: a comprehensive review and meta-analysis. Mathew S, et al. Alzheimer's & dementia (Amsterdam, Netherlands). 2025. PMID: 40525098
  71. Serum BDNF and progression to MCI in cognitively normal older adults: A prospective cohort study. Kim K, et al. The journal of prevention of Alzheimer's disease. 2025. PMID: 40414756
  72. Sex and APOE ε4 allele differences in longitudinal white matter microstructure in multiple cohorts of aging and Alzheimer's disease. Peterson A, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 39711105
  73. Sex-Based Differences in the Association of Epigenetic Age Acceleration with Alzheimer's Disease Biomarkers and Cognitive Measures. Edwards TA, et al. AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science. 2025. PMID: 40502223
  74. SLR: A Modified Logistic Regression Model with Sinkhorn Divergence for Alzheimer's Disease Classification. Zhan Q, et al. AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science. 2025. PMID: 40502270
  75. Tau pathway-based gene analysis on PET identifies CLU and FYN in a Korean cohort. Yi D, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 39625110
  76. Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex. Ossenkoppele R, et al. Nature neuroscience. 2025. PMID: 40670684
  77. The Cognitive Change Index in the Alzheimer's Disease Research Center setting: Self- and informant-ratings for perceived cognitive decline. Abughofah Y, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 41027849
  78. The dynamics of cognitive decline toward Alzheimer's disease progression: Results from ADSP-PHC's harmonized cognitive composites. Kang K, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 40538025
  79. The Dynamics of Cognitive Decline towards Alzheimer's Disease Progression: Results from ADSP-PHC's Harmonized Cognitive Composites. Kang K, et al. medRxiv : the preprint server for health sciences. 2025. PMID: 39830238
  80. The effect of Alzheimer's disease genetic factors on limbic white matter microstructure. Lorenz A, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 40219815
  81. The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging. Imam F, et al. Nature medicine. 2025. PMID: 40665048
  82. The Neighborhoods Study: Examining the social exposome in Alzheimer's disease and related dementias. George GC, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 41230793
  83. Trajectory of plasma lipidome associated with the risk of late-onset Alzheimer's disease: a longitudinal cohort study. Wang T, et al. EBioMedicine. 2025. PMID: 40592256
  84. Transcriptome analysis of early- and late-onset Alzheimer's disease in Korean cohorts. Han SW, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID: 39935412
  85. Traumatic Brain Injury and Alzheimer's Disease Biomarkers: A Systematic Review of Findings from Amyloid and Tau Positron Emission Tomography. Dybing KM, et al. Journal of neurotrauma. 2025. PMID: 39639808
  86. White Matter Abnormalities and Cognition in Aging and Alzheimer Disease. Peter C, et al. JAMA neurology. 2025. PMID: 40513084
  87. Alzheimer Disease Blood-Based Biomarkers: Translation from Research into Clinical Use. Ladic LA, et al. Clinical chemistry. 2024. PMID: 39361571
  88. Anxiety in late-life depression: Associations with brain volume, amyloid beta, white matter lesions, cognition, and functional ability. Kryza-Lacombe M, et al. International psychogeriatrics. 2024. PMID: 38268483
  89. APOE genotype-specific methylation patterns are linked to Alzheimer disease pathology and estrogen response. Panitch R, et al. Translational psychiatry. 2024. PMID: 38424036
  90. Association of amyloid and cardiovascular risk with cognition: Findings from KBASE. Chaudhuri S, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024. PMID: 39511852
  91. CYP1B1-RMDN2 Alzheimer's disease endophenotype locus identified for cerebral tau PET. Nho K, et al. Nature communications. 2024. PMID: 39304655
  92. Deciphering the tissue-specific functional effect of Alzheimer risk SNPs with deep genome annotation. Pugalenthi PV, et al. BioData mining. 2024. PMID: 39538253
  93. Deciphering the tissue-specific functional effect of Alzheimer risk SNPs with deep genome annotation. Pugalenthi PV, et al. Research square. 2024. PMID: 38405816
  94. Deep Trans-Omic Network Fusion for Molecular Mechanism of Alzheimer's Disease. Xie L, et al. Journal of Alzheimer's disease : JAD. 2024. PMID: 38728189
  95. Genetic and clinical correlates of two neuroanatomical AI dimensions in the Alzheimer's disease continuum. Wen J, et al. Translational psychiatry. 2024. PMID: 39368996
  96. Genome-wide transcriptome analysis of Aβ deposition on PET in a Korean cohort. Park T, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024. PMID: 39513963
  97. Genomic analysis of intracranial and subcortical brain volumes yields polygenic scores accounting for variation across ancestries. García-Marín LM, et al. Nature genetics. 2024. PMID: 39433889
  98. Gliovascular transcriptional perturbations in Alzheimer's disease reveal molecular mechanisms of blood brain barrier dysfunction. İş Ö, et al. Nature communications. 2024. PMID: 38902234
  99. GWAS of multiple neuropathology endophenotypes identifies new risk loci and provides insights into the genetic risk of dementia. Shade LMP, et al. Nature genetics. 2024. PMID: 39379761
  100. Individual bioenergetic capacity as a potential source of resilience to Alzheimer's disease. Arnold M, et al. medRxiv : the preprint server for health sciences. 2024. PMID: 38313266
  101. Integrating amyloid imaging and genetics for early risk stratification of Alzheimer's disease. He B, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024. PMID: 39285750
  102. Interpretable deep clustering survival machines for Alzheimer's disease subtype discovery. Hou B, et al. Medical image analysis. 2024. PMID: 38941858
  103. LD-informed deep learning for Alzheimer's gene loci detection using WGS data. Jo T, et al. medRxiv : the preprint server for health sciences. 2024. PMID: 39371140
  104. Longitudinal change in memory performance as a strong endophenotype for Alzheimer's disease. Archer DB, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024. PMID: 37985223
  105. miR-133b as a potential regulator of a synaptic NPTX2 protein in Alzheimer's disease. Han SW, et al. Annals of clinical and translational neurology. 2024. PMID: 39289904
  106. Pathway enrichment in genome-wide analysis of longitudinal Alzheimer's disease biomarker endophenotypes. Rosewood TJ, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024. PMID: 39440837
  107. Peripheral inflammation is associated with brain atrophy and cognitive decline linked to mild cognitive impairment and Alzheimer's disease. Liang N, et al. Scientific reports. 2024. PMID: 39075118
  108. Plasma miRNAs across the Alzheimer's disease continuum: Relationship to central biomarkers. Liu S, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024. PMID: 39291737
  109. Presenilin-1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stage. Joseph-Mathurin N, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024. PMID: 38380882
  110. Serum Bile Acids Improve Prediction of Alzheimer's Progression in a Sex-Dependent Manner. Chen T, et al. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2024. PMID: 38093507
  111. Sex, racial, and APOE-ε4 allele differences in longitudinal white matter microstructure in multiple cohorts of aging and Alzheimer's disease. Peterson A, et al. bioRxiv : the preprint server for biology. 2024. PMID: 38915636
  112. Sex-specific genetic architecture of late-life memory performance. Eissman JM, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024. PMID: 37984853
  113. Spatial transcriptomic patterns underlying amyloid-β and tau pathology are associated with cognitive dysfunction in Alzheimer's disease. Yu M, et al. Cell reports. 2024. PMID: 38244198
  114. The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022. Veitch DP, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024. PMID: 37698424
  115. The plasma miRNAome in ADNI: Signatures to aid the detection of at-risk individuals. Krüger DM, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024. PMID: 39291752
  116. Transcriptional risk scores in Alzheimer's disease: From pathology to cognition. Pyun JM, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024. PMID: 37563770
  117. Alzheimer's disease heterogeneity explained by polygenic risk scores derived from brain transcriptomic profiles. Chung J, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2023. PMID: 37166019
  118. An interpretable Alzheimer's disease oligogenic risk score informed by neuroimaging biomarkers improves risk prediction and stratification. Suh EH, et al. Frontiers in aging neuroscience. 2023. PMID: 37953885
  119. Brain-wide genome-wide colocalization study for integrating genetics, transcriptomics and brain morphometry in Alzheimer's disease. Bao J, et al. NeuroImage. 2023. PMID: 37634885
  120. Circular-SWAT for deep learning based diagnostic classification of Alzheimer's disease: application to metabolome data. Jo T, et al. EBioMedicine. 2023. PMID: 37806288
  121. Genome-Wide Association Analysis across Endophenotypes in Alzheimer's Disease: Main Effects and Disease Stage-Specific Interactions. Rosewood TJ, et al. Genes. 2023. PMID: 38002954
  122. Genomic loci influence patterns of structural covariance in the human brain. Wen J, et al. Proceedings of the National Academy of Sciences of the United States of America. 2023. PMID: 38127979
  123. Integrative Co-methylation Network Analysis Identifies Novel DNA Methylation Signatures and Their Target Genes in Alzheimer's Disease. Kim JP, et al. Biological psychiatry. 2023. PMID: 36150909
  124. Deep learning-based identification of genetic variants: application to Alzheimer's disease classification. Jo T, et al. Briefings in bioinformatics. 2022. PMID: 35183061
  125. Human microRNA (miR-20b-5p) modulates Alzheimer's disease pathways and neuronal function, and a specific polymorphism close to the MIR20B gene influences Alzheimer's biomarkers. Wang R, et al. Molecular psychiatry. 2022. PMID: 35087196
  126. Integrative analysis of DNA methylation and gene expression identifies genes associated with biological aging in Alzheimer's disease. Kim BH, et al. Alzheimer's & dementia (Amsterdam, Netherlands). 2022. PMID: 36187194
  127. PLCG2 is associated with the inflammatory response and is induced by amyloid plaques in Alzheimer's disease. Tsai AP, et al. Genome medicine. 2022. PMID: 35180881
  128. Association of peripheral blood DNA methylation level with Alzheimer's disease progression. Li QS, et al. Clinical epigenetics. 2021. PMID: 34654479
  129. Serum metabolites associated with brain amyloid beta deposition, cognition and dementia progression. Nho K, et al. Brain communications. 2021. PMID: 34396103
  130. Genome-wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology. Nho K, et al. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2020. PMID: 32755048
  131. Harnessing peripheral DNA methylation differences in the Alzheimer's Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease. Vasanthakumar A, et al. Clinical epigenetics. 2020. PMID: 32539856
  132. Progress in Polygenic Composite Scores in Alzheimer's and Other Complex Diseases. Chasioti D, et al. Trends in genetics : TIG. 2019. PMID: 30922659